Palo Alto Investors L.P. 13F annual report
Palo Alto Investors L.P. is an investment fund managing more than $863 billion ran by Angela Nguyen-dinh. There are currently 39 companies in Mrs. Nguyen-dinh’s portfolio. The largest investments include Insmed Inc and Biomarin Pharmaceutical, together worth $236 billion.
$863 billion Assets Under Management (AUM)
As of 7th August 2024, Palo Alto Investors L.P.’s top holding is 2,138,963 shares of Insmed Inc currently worth over $143 billion and making up 16.6% of the portfolio value.
Relative to the number of outstanding shares of Insmed Inc, Palo Alto Investors L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 1,130,167 shares of Biomarin Pharmaceutical worth $93 billion, whose value grew 5.8% in the past six months.
The third-largest holding is Amicus Therapeutics Inc worth $89.6 billion and the next is United Therapeutics Corp worth $85 billion, with 266,914 shares owned.
Currently, Palo Alto Investors L.P.'s portfolio is worth at least $863 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Palo Alto Investors L.P.
The Palo Alto Investors L.P. office and employees reside in Palo Alto, California. According to the last 13-F report filed with the SEC, Angela Nguyen-dinh serves as the Chief Compliance Officer at Palo Alto Investors L.P..
Recent trades
In the most recent 13F filing, Palo Alto Investors L.P. revealed that it had opened a new position in
Alnylam Pharmaceuticals Inc and bought 183,123 shares worth $44.5 billion.
This means they effectively own approximately 0.1% of the company.
Alnylam Pharmaceuticals Inc makes up
5.6%
of the fund's Health Care sector allocation and has grown its share price by 47.6% in the past year.
The investment fund also strengthened its position in Staar Surgical Co by buying
2,029 additional shares.
This makes their stake in Staar Surgical Co total 1,381,619 shares worth $65.8 billion.
Staar Surgical Co dropped 13.4% in the past year.
On the other hand, there are companies that Palo Alto Investors L.P. is getting rid of from its portfolio.
Palo Alto Investors L.P. closed its position in Alnylam Pharmaceuticals Inc on 14th August 2024.
It sold the previously owned 182,766 shares for $27.3 billion.
Angela Nguyen-dinh also disclosed a decreased stake in Insmed Inc by 0.5%.
This leaves the value of the investment at $143 billion and 2,138,963 shares.
One of the average hedge funds
The two most similar investment funds to Palo Alto Investors L.P. are Atika Capital Management and Quinn Opportunity Partners. They manage $863 billion and $862 billion respectively.
Angela Nguyen-dinh investment strategy
Palo Alto Investors L.P.’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 92.5% of
the total portfolio value.
The fund focuses on investments in the United States as
76.9% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
18% of the total holdings value.
On the other hand, small-cap stocks make up only 5.1% of the portfolio.
The average market cap of the portfolio companies is close to $7.37 billion.
The complete list of Palo Alto Investors L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Insmed Inc |
51.64%
2,138,963
|
$143,310,521,000 | 16.61% |
| Biomarin Pharmaceutical Inc. |
0.39%
1,130,167
|
$93,046,649,000 | 10.78% |
| Amicus Therapeutics Inc |
3.36%
9,029,843
|
$89,576,043,000 | 10.38% |
| United Therapeutics Corp |
0.32%
266,914
|
$85,025,455,000 | 9.85% |
| Biogen Inc |
0.31%
289,050
|
$67,007,571,000 | 7.76% |
| Staar Surgical Co. |
0.15%
1,381,619
|
$65,778,881,000 | 7.62% |
| Alnylam Pharmaceuticals Inc |
Opened
183,123
|
$44,498,889,000 | 5.16% |
| Acadia Pharmaceuticals Inc |
0.16%
2,418,841
|
$39,306,166,000 | 4.55% |
| Prothena Corp Plc |
0.18%
1,666,378
|
$34,394,042,000 | 3.99% |
| Sarepta Therapeutics Inc |
0.21%
201,683
|
$31,865,914,000 | 3.69% |
| Alnylam Pharmaceuticals Inc |
Closed
182,766
|
$27,314,379,000 | |
| AnaptysBio Inc |
0.47%
803,641
|
$20,139,243,000 | 2.33% |
| Iovance Biotherapeutics Inc |
0.17%
2,116,403
|
$16,973,552,000 | 1.97% |
| Revance Therapeutics Inc |
0.17%
5,257,086
|
$13,510,711,000 | 1.57% |
| Alkermes plc |
No change
495,592
|
$11,943,767,000 | 1.38% |
| Sage Therapeutics Inc |
0.50%
1,010,833
|
$10,977,646,000 | 1.27% |
| eHealth Inc |
13.46%
2,350,190
|
$10,646,361,000 | 1.23% |
| NovoCure Ltd |
No change
561,908
|
$9,625,484,000 | 1.12% |
| Align Technology, Inc. |
23.08%
37,772
|
$9,119,294,000 | 1.06% |
| Syndax Pharmaceuticals Inc |
No change
405,193
|
$8,318,612,000 | 0.96% |
| Acelyrin Inc |
No change
1,715,180
|
$7,563,944,000 | 0.88% |
| Nevro Corp |
No change
750,371
|
$6,318,124,000 | 0.73% |
| Cytokinetics Inc |
No change
111,717
|
$6,052,827,000 | 0.70% |
| Gossamer Bio, Inc. |
1.79%
6,277,093
|
$5,655,033,000 | 0.66% |
| Elevation Oncology Inc |
33.67%
1,800,106
|
$4,860,286,000 | 0.56% |
| Bluebird bio Inc |
1.60%
4,633,351
|
$4,560,144,000 | 0.53% |
| Karyopharm Therapeutics Inc |
No change
5,102,193
|
$4,426,663,000 | 0.51% |
| Verve Therapeutics Inc |
No change
575,817
|
$2,809,987,000 | 0.33% |
| Nuvation Bio Inc |
No change
772,652
|
$2,256,144,000 | 0.26% |
| Mirum Pharmaceuticals Inc |
No change
64,700
|
$2,212,093,000 | 0.26% |
| Relmada Therapeutics Inc |
No change
732,400
|
$2,197,200,000 | 0.25% |
| Taysha Gene Therapies, Inc. |
No change
811,268
|
$1,817,240,000 | 0.21% |
| Stoke Therapeutics, Inc. |
No change
125,861
|
$1,700,382,000 | 0.20% |
| Humana Inc. |
No change
3,985
|
$1,488,995,000 | 0.17% |
| Travere Therapeutics Inc |
No change
110,719
|
$910,110,000 | 0.11% |
| Vyne Therapeutics Inc Pipe |
No change
445,434
|
$877,505,000 | 0.10% |
| Aldeyra Therapeutics Inc |
No change
225,465
|
$746,289,000 | 0.09% |
| Aclaris Therapeutics Inc |
No change
569,832
|
$626,815,000 | 0.07% |
| Generation Bio Co. |
Opened
150,475
|
$424,340,000 | 0.05% |
| UroGen Pharma Ltd |
No change
24,500
|
$411,110,000 | 0.05% |
| No transactions found | |||
| Showing first 500 out of 40 holdings | |||
Hedge funds similar to Palo Alto Investors L.P.
- Aveo Capital Partners
- Grs Advisors
- Inspire Investing
- Rmr Wealth Builders
- Long Focus Capital Management
- Leuthold Group
- Towle & Co
- Atika Capital Management
- Quinn Opportunity Partners
- Ddd Partners
- Tran Capital Management, L.P.
- Middleton & Co Inc/ma
- Verus Partners
- Zuckerman Investment